ATR-101

DRUG3 trials

Sponsors

Millendo Therapeutics, Inc., Millendo Therapeutics US, Inc.

Conditions

ACCAdrenal CancerAdrenocortical CarcinomaCongenital Adrenal HyperplasiaCushing Syndrome

Phase 1

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

CompletedNCT01898715

Millendo Therapeutics, Inc.ACC, Adrenal Cancer, Adrenocortical Carcinoma

Start: 2013-08-13End: 2017-10-17Updated: 2017-11-06

Phase 2

A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

CompletedNCT02804178

Millendo Therapeutics, Inc.Congenital Adrenal Hyperplasia

Start: 2016-05-18End: 2017-08-17Updated: 2021-03-10

A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

TerminatedNCT03053271

Millendo Therapeutics US, Inc.Cushing Syndrome

Start: 2017-04-13End: 2019-08-12Updated: 2021-03-02

Related Papers

A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.

2020-01-2741 citations

SUN-357 Trial in Progress: A Multicenter, Dose-titration, Open-Label Phase 2b Study of Nevanimibe Hydrochloride, a Novel ACAT1 Inhibitor, for the Treatment of Classic Congenital Adrenal Hyperplasia

Journal of the Endocrine Society2019-04-01

ATR-101 phase 1 clinical study for adrenocortical carcinoma.

Journal of Clinical Oncology2015-05-205 citations

Phase 1 study of ATR-101 in adrenocortical carcinoma (ACC): ATR-101-001.

Journal of Clinical Oncology2014-05-20